Compare UTZ & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | PCRX |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 912.7M | 1.0B |
| IPO Year | 2018 | 2010 |
| Metric | UTZ | PCRX |
|---|---|---|
| Price | $8.25 | $22.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $13.00 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 1.8M | 761.1K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | 0.01 | ★ 0.16 |
| Revenue | ★ $1,438,800,000.00 | $541,533,000.00 |
| Revenue This Year | $4.95 | $9.77 |
| Revenue Next Year | $1.59 | $9.71 |
| P/E Ratio | $857.50 | ★ $137.50 |
| Revenue Growth | 2.09 | ★ 26.04 |
| 52 Week Low | $8.37 | $18.80 |
| 52 Week High | $14.67 | $27.99 |
| Indicator | UTZ | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.25 | 49.39 |
| Support Level | N/A | $20.41 |
| Resistance Level | $10.74 | $23.82 |
| Average True Range (ATR) | 0.30 | 0.97 |
| MACD | -0.10 | -0.02 |
| Stochastic Oscillator | 7.64 | 50.80 |
Utz Brands Inc is a manufacturer of branded salty snacks. It produces a broad offering of salty snacks, including potato chips, tortilla chips, pretzels, cheese snacks, pork skins, pub/party mixes, and other snacks. Its iconic portfolio of authentic, craft, and better-for-you (BFY) brands, which includes Utz, Zapp's, On The Border, Golden Flake, and Boulder Canyon, among others, enjoys household penetration in the United States, where its products can be found in approximately half of U.S. household. The company operates in eight manufacturing facilities with a broad range of capabilities, and its products are distributed nationally to grocery, mass, club, convenience, drug, e-commerce and other retailers through direct shipments, distributors, and approximately 2,500 DSD routes.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.